Dr. Adriana Soto, presented data on Zanidatamap, a bispecific antibody approved by the FDA for treating HER2-positive biliary tract cancer. The therapy demonstrated a 41.3% objective response rate and 12-month overall survival in a phase 2 trial, with common side effects including diarrhea, infusion reactions, and elevated liver enzymes. Presented at 2025 SPS Puerto Rico.